Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

BROLUCIZUMAB-DBLL vs BROMOCRIPTINE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

BROLUCIZUMAB-DBLL vs BROMOCRIPTINE: Safety Overview

Metric BROLUCIZUMAB-DBLL BROMOCRIPTINE
Total FAERS Reports 2,802 864
Deaths Reported 198 75
Death Rate 7.1% 8.7%
Hospitalizations 170 308
Average Patient Age 76.6 yrs 41.4 yrs
% Female Patients 57.3% 57.5%
FDA Approval Date N/A Approved Prior to Jan 1, 1982
Manufacturer N/A Zydus Pharmaceuticals USA Inc.
Route N/A ORAL
Marketing Status Prescription Prescription